Immutep Ltd (IMM) reported that it will provide an update on the ongoing TACTI-mel Phase I clinical trial and the clinical development of eftilagimod alpha (“efti” or “IMP321”) in a global webcast, including a Q&A session
http://crweworld.com/article/news-provided-by-globenewswire/1031729/immutep-to-host-eftilagimod-alpha-clinical-development-update-global-webcast
Immutep Ltd (IMM) reported that it will provide an update on the...
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
31.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $486.6M | |||
| Open | High | Low | Value | Volume |
| 31.0¢ | 31.8¢ | 30.3¢ | $628.6K | 2.023M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 20 | 138292 | 31.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.5¢ | 519690 | 42 |
View Market Depth
| Last trade - 15.39pm 27/11/2024 (20 minute delay) ? |
| IMM (ASX) Chart |
